MAGENTA is a clinical trial focused on evaluating the efficacy of IGC-AD1, an investigational drug for Agitation in Alzheimer's dementia. Agitation is one of the most common neuropsychiatric symptoms in Alzheimer’s and can disrupt daily life for both patients and caregivers. Understanding and managing these symptoms is essential for improving the quality of life for those affected.
Our Phase 2 clinical trial could play a crucial role in advancing treatments for agitation in Alzheimer’s dementia, offering new hope to many families. If you or someone you know is interested in participating in the MAGENTA Trial, click here to learn more.
JOIN OUR TRIAL
IGC-AD1 is an innovative oral solution designed to target and alleviate symptoms of agitation in Alzheimer's patients. This drug is currently being tested in a Phase 2 clinical trial to assess its safety and effectiveness.
The promise
of IGC-AD1
LOCATE A CLINICAL TRIAL SITE NEAR YOU
MAGENTA is a clinical trial focused on evaluating the efficacy of IGC-AD1, a new treatment for Agitation in Alzheimer's dementia.
© 2025 All Rights Reserved.
The study is sponsored by IGC Pharma LLC
